PharmaPoint Meningococcal Vaccines

4.2.3 Exposure is Highest for Those Traveling to the African Meningitis Belt30
4.3 Global Trends 31
4.3.1 US 31
4.3.2 5EU 32
4.3.3 Australia 33
4.3.4 Brazil 33
4.4 Forecast Methodology 34
4.4.1 Sources Used 36
4.4.2 Forecast Assumptions and Methods 39
4.4.3 Sources Not Used 44
4.5 Epidemiology Forecast of Meningococcal Disease (2012-2022) 44
4.5.1 Incident Cases of Meningococcal Disease 44
4.5.2 Age-Specific Incident Cases of Meningococcal Disease 46
4.5.3 Incident Cases of Meningococcal Disease by Serogroup 48
4.6 Discussion 50
4.6.1 Conclusions on Epidemiological Trends 50
4.6.2 Limitations of the Analysis 52
4.6.3 Strengths of the Analysis 52
5 Disease Management 53
5.1 Meningococcal Immunization Policy 54
5.2 US 56
5.2.1 Meningococcal Immunization Recommendations and Policies 56
5.2.2 Clinical Practice 59
5.3 France 61
5.3.1 Meningococcal Immunization Recommendations and Policies 61
5.3.2 Clinical Practice 64
5.4 Germany 65
5.4.1 Meningococcal Immunization Recommendations and Policies 65
5.4.2 Clinical Practice 66
5.5 Italy 67
5.5.1 Meningococcal Immunization Recommendations and Policies 67
5.5.2 Clinical Practice 68
5.6 Spain 69
5.6.1 Meningococcal Immunization Recommendations and Policies 69
5.6.2 Clinical Practice 70
5.7 UK 72
5.7.1 Meningococcal Immunization Recommendations and Policies 72
5.7.2 Clinical Practice 74
5.8 Japan 75
5.8.1 Meningococcal Immunization Recommendations and Policies 75
5.8.2 Clinical Practice 76
5.9 Australia 76
5.9.1 Meningococcal Immunization Recommendations and Policies 76
5.9.2 Clinical Practice 78
5.10 Brazil 80
5.10.1 Meningococcal Immunization Recommendations and Policies 80
5.10.2 Clinical Practice 81
3